Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 4,841 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 4,841 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $201,191.96. Following the transaction, the chief executive officer now owns 603,886 shares of the company’s stock, valued at $25,097,502.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Twist Bioscience Trading Up 5.3 %

Shares of NASDAQ:TWST opened at $45.42 on Thursday. The firm has a 50 day simple moving average of $43.64 and a 200-day simple moving average of $45.43. Twist Bioscience Co. has a twelve month low of $15.85 and a twelve month high of $60.90. The company has a market capitalization of $2.66 billion, a PE ratio of -11.89 and a beta of 1.78.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of TWST. BNP Paribas Financial Markets boosted its holdings in shares of Twist Bioscience by 34.8% in the first quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock valued at $5,895,000 after acquiring an additional 44,349 shares in the last quarter. SageView Advisory Group LLC purchased a new position in shares of Twist Bioscience during the 1st quarter worth approximately $1,144,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Twist Bioscience in the 1st quarter valued at approximately $300,000. Sei Investments Co. boosted its stake in shares of Twist Bioscience by 32.7% in the first quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after buying an additional 55,124 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC raised its position in Twist Bioscience by 38.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after acquiring an additional 37,376 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TWST. Barclays lowered their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Evercore ISI boosted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Robert W. Baird lifted their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Finally, Leerink Partners upped their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.